E156 Micro-Paper · Africa Clinical Trials

North Africa vs Sub-Saharan Divide

North Africa (Egypt, Morocco, Tunisia) operates in a fundamentally different res...

Africa Trials
3,515
US Trials
159,433
Gap Ratio
45x
Nations
54
Africa hosts 23,873 trials across 54 nations with extreme geographic concentration.
North Africa vs Sub-Saharan Divide by Country Egypt: 11752 Algeria: 114 Morocco: 162 Tunisia: 540 Senegal: N/A Ghana: N/A Nigeria: N/A Cameroon: N/A DRC: N/A Ethiopia: N/A Kenya: N/A Uganda: N/A Tanzania: N/A Rwanda: N/A South Africa: N/A Egy 11752 Tun 540 Mor 162 Alg 114 12 11752
Contribution Breakdown 11752 Egypt 540 Tunisia 162 Morocco 114 Algeria 12 Libya
Growth 2010-2026 Before After Africa 0 0 US 0 0 Europe 0 0
Enrollment Distribution Africa Reference 5000 10000 15000 20000
No data
North Africa vs Sub-Saharan Divide Lorenz Curve 0% 0% 25% 25% 50% 50% 75% 75% 100% 100% Gini = 0.760
Research Profile Volume Growth Phase3 Complete Diversity
Phase Distribution Africa US Europe Phase 1 11 134.7 88.3 Phase 2 20 253.5 61.1 Phase 3 52 718.5 499.3 Phase 4 12 139.6 103.2 718.5 11
Why It Matters

North Africa (Egypt, Morocco, Tunisia) operates in a fundamentally different research ecosystem than Sub-Saharan Africa — higher GDP, stronger regulatory frameworks, Mediterranean clinical trial networks, and proximity to European sponsors.

In the spatial mapping of African clinical research, does the pattern of north africa vs sub-saharan divide reveal structural inequity in African research investment? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation. Africa registered 3,515 relevant trials compared to 159,433 in the United States, revealing an 45-fold absolute gap in research volume. The Theil index of 1.305 confirmed between-country inequality, with decomposition showing most disparity arising from inter-regional gaps. These findings reveal a geographic research monopoly where most African nations remain functionally invisible in the clinical evidence landscape. Interpretation is limited by reliance on ClinicalTrials.gov alone, which may undercount locally registered African studies.
Question

In the spatial mapping of African clinical research, does the pattern of north africa vs sub-saharan divide reveal structural inequity in African research investment?

Dataset

This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.

Method

gov through April 2026.

Primary Result

Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation.

Robustness

Africa registered 3,515 relevant trials compared to 159,433 in the United States, revealing an 45-fold absolute gap in research volume.

Interpretation

The Theil index of 1.

Boundary

305 confirmed between-country inequality, with decomposition showing most disparity arising from inter-regional gaps.

Extra

These findings reveal a geographic research monopoly where most African nations remain functionally invisible in the clinical evidence landscape.

Extra

Interpretation is limited by reliance on ClinicalTrials.

Extra

gov alone, which may undercount locally registered African studies.